{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:20:58Z","timestamp":1793917258657,"version":"4.8.0"},"reference-count":37,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"crossref","award":["BRC Precision Medicine Cluster H8R01081"],"award-info":[{"award-number":["BRC Precision Medicine Cluster H8R01081"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR Research Capability Funding","award":["RCF17\/043"],"award-info":[{"award-number":["RCF17\/043"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2019,2,24]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors like anti-programmed cell death protein 1 (PD-1) drugs Nivolumab and Pembrolizumab and anti-cytotoxic T-lymphocyte associated (CTLA-4) drug Ipilimumab have become standard of care in many metastatic cancers. Immunotherapy-related hepatitis and cholangitis present a diagnostic and management challenge, being rare and incompletely characterised. We aim to report the incidence, features and treatments used for this in a real-world setting and to identify useful biomarkers, which can be used to predict effective use of steroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective review of 453 patients started on immunotherapy over 7 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Tertiary hepatology and oncology centre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>21 patients identified with immunotherapy-related hepatotoxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Hepatitis was most common in those receiving dual therapy (incidence 20%), with 75% of Grade 4 hepatitis cases occurring with ipilimumab-containing regimens. Corticosteroid monotherapy is first line treatment, but doses above 60\u2009mg OD prednisolone do not demonstrate any additional benefit in time to hepatitis resolution. The alanine transaminase (ALT) reduction in steroid-responsive hepatitis is typically rapid (with a halving of ALT within 11 days). The commencement of additional immunosuppression (typically mycophenolate) appears safe and prompts a more rapid fall in ALT than corticosteroid use alone. Infliximab was safely used twice as hepatitis treatment. We also describe one patient with rare immunotherapy-induced biliary disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Vigilance is required for detection of immunotherapy-associated liver disease as, other than dual immunotherapy, we can identify no predictive factors for its development. Our data suggest that corticosteroid response is not dependent on the higher dosing regimens. Early escalation of immunosuppression may be of benefit in the absence of a rapid response to corticosteroids.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2018-101146","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T17:15:31Z","timestamp":1553274931000},"page":"364-371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":98,"title":["Immunotherapy-related hepatitis: real-world experience from a tertiary centre"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1715-2281","authenticated-orcid":false,"given":"Vincent","family":"Cheung","sequence":"first","affiliation":[{"name":"Gastroenterology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Gupta","sequence":"additional","affiliation":[{"name":"Gastroenterology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[{"name":"Oncology, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Middleton","sequence":"additional","affiliation":[{"name":"Oncology, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane D","family":"Collier","sequence":"additional","affiliation":[{"name":"Hepatology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Simmons","sequence":"additional","affiliation":[{"name":"Gastroenterology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[{"name":"Gastroenterology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Brain","sequence":"additional","affiliation":[{"name":"Gastroenterology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy F","family":"Cobbold","sequence":"additional","affiliation":[{"name":"Hepatology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"2025090709430847000_10.4.364.1","unstructured":"Wolchok JD , Chiarion-Sileni V , Gonzalez R , et al . Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017."},{"key":"2025090709430847000_10.4.364.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2025090709430847000_10.4.364.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025090709430847000_10.4.364.4","doi-asserted-by":"crossref","unstructured":"Gandhi L , Rodr\u00edguez-Abreu D , Gadgeel S , et al . Pembrolizumab plus chemotherapy in metastatic Non\u2013Small-Cell lung cancer. N Engl J Med 2018.","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025090709430847000_10.4.364.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"2025090709430847000_10.4.364.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2025090709430847000_10.4.364.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu205"},{"key":"2025090709430847000_10.4.364.8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0496"},{"key":"2025090709430847000_10.4.364.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"2025090709430847000_10.4.364.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025090709430847000_10.4.364.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2025090709430847000_10.4.364.12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2025090709430847000_10.4.364.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2140-5"},{"key":"2025090709430847000_10.4.364.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"2025090709430847000_10.4.364.15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"2025090709430847000_10.4.364.16","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"2025090709430847000_10.4.364.17","first-page":"1","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"2025090709430847000_10.4.364.18","doi-asserted-by":"crossref","unstructured":"K\u00e4hler KC , Eigentler TK , Gesierich A , et al . Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 2018;67.doi:10.1007\/s00262-018-2134-z","DOI":"10.1007\/s00262-018-2134-z"},{"key":"2025090709430847000_10.4.364.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008"},{"key":"2025090709430847000_10.4.364.20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00281-016-0595-8","article-title":"Cancer immunotherapy in patients with preexisting autoimmune disorders","volume":"39","author":"Donia","year":"2017","journal-title":"Semin Immunopathol"},{"key":"2025090709430847000_10.4.364.21","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: american Society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025090709430847000_10.4.364.22","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090709430847000_10.4.364.23","unstructured":"U.S. Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE). version 5.0. UpToDate, 2017."},{"key":"2025090709430847000_10.4.364.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"2025090709430847000_10.4.364.25","doi-asserted-by":"crossref","unstructured":"Suzman DL , Pelosof L , Rosenberg A , et al . Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018;38.doi:10.1111\/liv.13746","DOI":"10.1111\/liv.13746"},{"key":"2025090709430847000_10.4.364.26","doi-asserted-by":"crossref","unstructured":"Samaan MA , Pavlidis P , Papa S , et al . Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management. Nat Rev Gastroenterol Hepatol 2018;15.doi:10.1038\/nrgastro.2018.14","DOI":"10.1038\/nrgastro.2018.14"},{"key":"2025090709430847000_10.4.364.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"2025090709430847000_10.4.364.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9939-6"},{"key":"2025090709430847000_10.4.364.29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30678"},{"key":"2025090709430847000_10.4.364.30","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025090709430847000_10.4.364.31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313369"},{"key":"2025090709430847000_10.4.364.32","doi-asserted-by":"crossref","unstructured":"Brahmer JR , Lacchetti C , Schneider BJ , et al . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american Society of clinical oncology clinical practice guideline. J Clin Oncol 2018.","DOI":"10.1200\/JOP.18.00005"},{"key":"2025090709430847000_10.4.364.33","doi-asserted-by":"crossref","unstructured":"Chmiel KD , Suan D , Liddle C , et al . Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011;29.doi:10.1200\/JCO.2010.32.2206","DOI":"10.1200\/JCO.2010.32.2206"},{"key":"2025090709430847000_10.4.364.34","doi-asserted-by":"crossref","unstructured":"Puzanov I , Diab A , Abdallah K , et al . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working Group. J Immunother Cancer 2017;5.doi:10.1186\/s40425-017-0300-z","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025090709430847000_10.4.364.35","doi-asserted-by":"crossref","unstructured":"Huffman BM , Kottschade LA , Kamath PS , et al . Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma. Am J Clin Oncol 2017.","DOI":"10.1097\/COC.0000000000000374"},{"key":"2025090709430847000_10.4.364.36","unstructured":"Thompson JA , Schneider BJ , Brahmer J , et al . Management of Immunotherapy-Related toxicities. NCCN Guidel 2018."},{"key":"2025090709430847000_10.4.364.37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.21037\/jgo.2017.08.14","article-title":"Approach and management of checkpoint inhibitor-related immune hepatitis","volume":"9","author":"Sanjeevaiah","year":"2018","journal-title":"J Gastrointest Oncol"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2018-101146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:43:14Z","timestamp":1757263394000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2018-101146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,9,6]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/flgastro-2018-101146"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2018-101146","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]}}}